• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

May 23, 2007 Approval Letter - Procleix Ultrio Assay

May 23, 2007

Our STN: BL 125113/2

Gen-Probe Incorporated
Attn: Leanne M. Kiviharju
10210 Genetic Center Drive
San Diego, CA 92121

Dear Ms. Kiviharju:

We have approved your request to supplement your biologics license application for your Procleix Ultrio Assay to add the Procleix TIGRIS System for use with the Procleix Ultrio Assay.

Your August 23, 2006 written commitment to perform a postmarketing study to demonstrate detection of window period donations for HBV infection remains in effect and eventual licensure of The Procleix Ultrio Assay on the Procleix TIGRIS system for screening for HBV will depend on the TIGRIS being able to detect HBV window period donations in the end user setting.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h and FDA Form 2567 as appropriate.

We will include information contained in the above-referenced supplement in your biologics license application file.

Sincerely yours,

--- signature ---

 

Jay S. Epstein, M.D.
Director
Office of Blood Research and Review
Center for Biologics Evaluation and Research

 

Return to the Procleix Ultrio page